SCHEMBL20956169

SCHEMBL20956169

CC(C)OC(=O)c1cnc2[nH]ccc2c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.50
PRKCI P41743 1/20 0.50
JAK1 P23458 8/20 0.46
JAK3 P52333 8/20 0.45
NUDT1 P36639 1/20 0.42
MGLL Q99685 3/20 0.39
JAK2 O60674 4/20 0.39
P2RX7 Q99572 2/20 0.38
TYK2 P29597 1/20 0.38
DAPK3 O43293 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PAK4 O96013 1/20 0.38
ABL1 P00519 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
MET P08581 1/20 0.38
PDGFRB P09619 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30823440 1.00 AXL (0.50) AXLPRKCIJAK1JAK3NUDT1
SCHEMBL2115690 0.86 AXL (0.55) AXLPRKCIJAK1JAK3NUDT1
SCHEMBL30985188 0.86 AXL (0.55) AXLPRKCIJAK1JAK3NUDT1
SCHEMBL29477133 0.81 NUDT1 (0.65) AXLPRKCIJAK1JAK3NUDT1
SCHEMBL20956198 0.81 AXL (0.50) AXLPRKCIJAK1JAK3NUDT1
SCHEMBL566667 0.81 NUDT1 (0.65) AXLPRKCIJAK1JAK3NUDT1
Hydrochloric Acid SCHEMBL29234028 0.80 NUDT1 (0.64) AXLPRKCIJAK1JAK3NUDT1
Hydrochloric Acid SCHEMBL29477135 0.80 NUDT1 (0.64) AXLPRKCIJAK1JAK3NUDT1
SCHEMBL20956287 0.79 NUDT1 (0.52) AXLPRKCIJAK1JAK3NUDT1
SCHEMBL1154022 0.78 AXL (0.56) AXLPRKCIJAK1JAK3NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062410-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS INC (US) 2026-03-05 US disclosed
US-12281111-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. (US) 2025-04-22 US disclosed
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2024-02-29 US disclosed
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2024-02-29 US disclosed
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2024-02-29 US disclosed
US-11739086-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. (US) 2023-08-29 US disclosed
US-11739086-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. (US) 2023-08-29 US disclosed
US-11739086-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. (US) 2023-08-29 US disclosed
US-20210284637-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2021-09-16 US disclosed
US-20210284637-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2021-09-16 US disclosed
US-10981906-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. (US) 2021-04-20 US disclosed
US-10981906-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. (US) 2021-04-20 US disclosed
US-10800775-B2 Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same ACLARIS THERAPEUTICS, INC. (US) 2020-10-13 US disclosed
US-10800775-B2 Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same ACLARIS THERAPEUTICS, INC. (US) 2020-10-13 US disclosed
US-20190135807-A1 PYRAZOLYL PYRROLO[2,3-B]PYRMIDINE-5-CARBOXYLATE ANALOGS AND METHODS OF MAKING THE SAME ACLARIS THERAPEUTICS, INC. 2019-05-09 US disclosed
US-20190135807-A1 PYRAZOLYL PYRROLO[2,3-B]PYRMIDINE-5-CARBOXYLATE ANALOGS AND METHODS OF MAKING THE SAME ACLARIS THERAPEUTICS, INC. 2019-05-09 US disclosed
US-20190135808-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2019-05-09 US disclosed
US-20190135808-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981906-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same JAK3, JAK1, JAK2 AXL 1363/4885PRKCI 197/4885JAK1 2/4885
US-12281111-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same JAK3, JAK1, JAK2 AXL 1363/4885PRKCI 197/4885JAK1 2/4885
US-20190135807-A1 PYRAZOLYL PYRROLO[2,3-B]PYRMIDINE-5-CARBOXYLATE ANALOGS AND METHODS OF MAKING THE SAME JAK3, JAK1, JAK2 AXL 1120/4885PRKCI 312/4885JAK1 2/4885
US-20260062410-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME JAK3, JAK1, JAK2 AXL 1887/4885PRKCI 293/4885JAK1 2/4885
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME JAK3, JAK1, JAK2 AXL 1363/4885PRKCI 197/4885JAK1 2/4885
US-20210284637-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME JAK3, JAK1, JAK2 AXL 1363/4885PRKCI 197/4885JAK1 2/4885
US-11739086-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same JAK3, JAK1, JAK2 AXL 1363/4885PRKCI 197/4885JAK1 2/4885
US-20190135808-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME JAK3, JAK1, JAK2 AXL 1363/4885PRKCI 197/4885JAK1 2/4885
US-10800775-B2 Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same JAK3, JAK1, JAK2 AXL 1120/4885PRKCI 312/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.